HomeInvestors & MediaNews
- The posters will be disclosed on April 20
- Both programs recently received U.S. Phase 1 IND approvals… Initial clinical data expected to be presented in 2027
Seoul (South Korea) – March 19, 2026, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will participate in the American Association for Cancer Research (AACR) Annual Meeting and present non-clinical data on ABL206 (NEOK001) and ABL209 (NEOK002) in poster sessions.
The AACR Annual Meeting is a global event where pharmaceutical and biotech companies, researchers, healthcare professionals, and patients gather to share the latest research findings. This year’s meeting will be held from April 17 to 22 at the San Diego Convention Center in California, USA.
ABL206 (NEOK001) and ABL209 (NEOK002), which will be introduced in poster presentations at the event, are bispecific antibody-drug conjugate (ADC) pipelines developed by ABL Bio. NEOK Bio, which holds the clinical development and global development rights rights to both pipelines, is rapidly initiating clinical development for both programs after receiving Investigational New Drug (IND) approvals for Phase 1 trials from the U.S. Food and Drug Administration (FDA). ABL206 (NEOK001) targets both B7-H3 and ROR1, while ABL209 (NEOK002) targets EGFR and MUC1. Both pipelines utilize a payload based on a topoisomerase I inhibitor.
The posters for ABL206 (NEOK001) and ABL209 (NEOK002) will be presented on April 20 during the session titled “Antibody-Drug Conjugates and Linker Engineering 2.”
According to the abstracts, in preclinical studies, ABL206 (NEOK001) demonstrated improved efficacy and safety compared to single-antibody ADCs targeting either ROR1 or B7-H3 in both in vitro and in vivo settings. It also showed overall favorable tolerability in GLP toxicity studies conducted in non-human primates. ABL209 (NEOK002) likewise exhibited strong anticancer activity while reducing EGFR-related toxicity.
CEO Sang Hoon Lee of ABL Bio stated, “ABL206 (NEOK001) and ABL209 (NEOK002) are promising next-generation ADC pipelines with encouraging preclinical data. Clinical development of both programs is being carried out by NEOK Bio in the United States. NEOK Bio, together with ADC development experts, has established an optimal clinical strategy and aims to present initial Phase 1 clinical data in 2027. In addition, ABL Bio is actively advancing next-generation ADC research to follow ABL206 (NEOK001) and ABL209 (NEOK002), and we will accelerate R&D efforts to disclose subsequent pipelines as soon as possible.”
About ABL Bio
ABL Bio is advancing a diverse pipeline of preclinical and clinical-stage programs based on its proprietary bispecific antibody platform, Grabody. Clinical development programs for 10 pipeline assets—including ABL301 (SAR446159), ABL001 (Tovecimig), ABL111 (Givastomig), ABL503 (Ragistomig), ABL105 (Nesfrotamig), ABL104 (YH32364), ABL103, ABL202 (CS5001/LCB71), ABL206 (NEOK001), and ABL209 (NEOK002)—are underway across multiple countries, including the United States, China, Australia, and South Korea.
Following the completion of its Phase 1 clinical trial in the United States, further development of ABL301 (SAR446159) will be led by Sanofi. ABL001 (Tovecimig), currently being evaluated in a Phase 2/3 clinical trial for patients with biliary tract cancer, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). ABL111 (Givastomig), which is being co-developed with NovaBridge, has initiated a Phase 2 clinical trial in combination with nivolumab and chemotherapy, and plans to present additional data from the Phase 1b study at a global conference in the second half of this year.
In addition, multiple preclinical programs—including bispecific ADCs and dual-payload ADCs—are being continuously advanced through research and development.